Results 111 to 120 of about 21,135 (199)

Prolonged QT Interval in HIV-1 Infected Humanized Mice Treated Chronically with Dolutegravir/Tenofovir Disoproxil Fumarate/Emtricitabine. [PDF]

Int J Mol Sci
Namvaran A, Garcia JV, Ramasamy M, Nguyen K, Tavakkoli Ghazani F, Hackfort BT, Dash PK, Fisher RE, Edagwa B, Gorantla S, Bidasee KR.   +10 more
europepmc   +1 more source

Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies. [PDF]

J Infect Dis
Cox S, Andreatta K, Hendricks MR, Li J, Kintu A, Brown LB, Carter CC, Callebaut C.   +7 more
europepmc   +1 more source

Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana [PDF]

, 2015

core   +1 more source

Efficacy and Safety of Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate for Preventing Mother-to-Child Transmission of Hepatitis B in Treatment-Naïve mothers: An Observational Study. [PDF]

Virol J
Yang X, Chen J, Duan L, Li X, Cheng W, Chen Y, Huang Y, Huang Z.   +7 more
europepmc   +1 more source

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France [PDF]

, 2016

core   +1 more source

The efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in treatment-naïve and treatment-experienced patients with HIV. [PDF]

Ann Med
Yang H, Li M, Liu Q, Zeng Q, Yuan J.
europepmc   +1 more source

Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083. [PDF]

Clin Infect Dis
Brown TT, Arao RF, Warsi M, Phanuphak N, Vasconcelos R, Oyedele T, Sullivan PA, Hanscom B, Rooney JF, Rinehart AR, McCauley M, Grinsztejn B, Landovitz RJ.   +12 more
europepmc   +1 more source

A retrospective comparative study of tenofovir alafenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients: Renal and bone safety versus antiviral efficacy. [PDF]

Medicine (Baltimore)
Wang L, Pi G, Lu D, Wang Y, Sun W.
europepmc   +1 more source

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use [PDF]

, 2015

core   +1 more source

Assessment of the risk of discontinuation of tenofovir disoproxil fumarate after delivery and the benefit of continued treatment in patients with immune tolerance. [PDF]

Front Med (Lausanne)
Liang H, Liang H, Hu B, Huang L, Liang H, Su M, Wang R, Su T, Li Q, Feng Y, Jiang J.   +10 more
europepmc   +1 more source